165 related articles for article (PubMed ID: 15310550)
1. Insulin: thoroughly modern therapy.
Isley WL
Endocr Pract; 2004; 10(3):289-90. PubMed ID: 15310550
[No Abstract] [Full Text] [Related]
2. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
3. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
4. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
5. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
Hamid Z; Simmons DL
Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
[No Abstract] [Full Text] [Related]
6. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
[No Abstract] [Full Text] [Related]
7. Role of metformin in type II diabetes.
Epstein S
Cleve Clin J Med; 1995; 62(5):278-9. PubMed ID: 7586481
[No Abstract] [Full Text] [Related]
8. Insulin initiation in Type 2 diabetes.
Page S
Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
[No Abstract] [Full Text] [Related]
9. Pharmacological treatment of type 2 diabetes.
Hermans MP; Buysschaert M
Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468
[No Abstract] [Full Text] [Related]
10. Insulin as initial therapy for type 2 diabetes is not in the patient's best interest.
Bell DS
Endocr Pract; 2004; 10(3):208-12. PubMed ID: 15310539
[No Abstract] [Full Text] [Related]
11. [Modern methods of correction of systemic inflammation and insulin resistance by patients with coronary heart disease and diabetes mellitus type 2].
Rasin MS; Shaenko ZA
Lik Sprava; 2014; (3-4):60-5. PubMed ID: 25286600
[TBL] [Abstract][Full Text] [Related]
12. [Tough glucose reduction necessary in newly diagnosed diabetes].
Rydén M
Lakartidningen; 2010 Nov 10-16; 107(45):2810-4. PubMed ID: 21179867
[No Abstract] [Full Text] [Related]
13. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
14. Incorporating New Medications in Diabetes Care.
Comi RJ
Ann Intern Med; 2015 Nov; 163(9):719-20. PubMed ID: 26458033
[No Abstract] [Full Text] [Related]
15. New therapeutic options: management strategies to optimize glycemic control.
Sisam DA
J Am Osteopath Assoc; 2011 Apr; 111(4):300; author reply 300. PubMed ID: 21562302
[No Abstract] [Full Text] [Related]
16. Insulin sensitizers: past, present and future.
Siddiqui NI
Mymensingh Med J; 2005 Jan; 14(1):1-2. PubMed ID: 15695942
[No Abstract] [Full Text] [Related]
17. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Hanefeld M
Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
[TBL] [Abstract][Full Text] [Related]
18. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus.
Sauer WH; Cappola AR; Berlin JA; Kimmel SE
Am J Cardiol; 2006 Mar; 97(5):651-4. PubMed ID: 16490431
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
20. beta-cell function and anti-diabetic pharmacotherapy.
Del Prato S; Bianchi C; Marchetti P
Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
